Through the acquisition of Welsh BBI group on Tuesday, Novo Holdings is demonstrating that the diagnostics area is an important field of interest for the Danish life science investor.
It has been seven years since Novo Holdings last took over majority ownership, and according to Christoffer Søderberg and Sibel Arnes from Novo Holdings' Principal Investments team, a lot is happening in this area, which makes it a highly interesting field for Novo Holdings.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Rumored purchase of GN Group could mean divestment of hearing aid division, says media
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
EMA publishes new plan to support antibiotic development
Drug-resistant bacteria kill hundreds of thousands of people every year, and national regulatory forces across the world are now coming together to ensure a uniform approach to clinical trials for antibiotics.
Consultant Manager 
Clinical Trial Manager 
Account Manager 
Senior Manager, Clinical Trial Budget 
Senior QA Specialist 
Procurement Manager, Direct Materials 
Industrial Designer- Design Engineer 
Project Manager & Scrum Master 
Cell Culture Scientist/Senior Scientist 
(Senior) Drug Substance Specialist 
Director Global Engineering 
Key Account Manager, Europe and Asia 
Senior Project Manager (GMP - Life Science)